NIH Launches LUCA Biologics to Develop Live Biotherapeutics for Women’s Health

 NIH Launches LUCA Biologics to Develop Live Biotherapeutics for Women’s Health

Shots:

  • NIH has launched LUCA Biologics in Cambridge, Massachusetts focusing on women’s health by initially targeting UTI with its anticipated clinical study and initiation of recruitment of patients in H2’19
  • LUCA initiates with a strain bank and gene catalog developed over 15yrs. from Gates Foundation and NIH-funded research and has built a metagenomic and metatranscriptomic platform to identify & validate strains modulating vaginal and urogenital microbiome
  • LUCA Biologic is a biotechnological company developing therapies focusing on women’s health with a pipeline targeting UTI, bacterial vaginosis (BV), and preterm birth (PTB)

Click here to­ read full press release/ article | Ref: PRNewswire | Image: GBI Monthly

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post